Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops

Rejuvenation Research

Volumn 7, Issue 3, 2004, Pages 186-198

  Babizhayev, Mark A ^a,b,c  

^a Innovative Vision Products Incorporated   (United States)

^b MOSCOW HELMHOLTZ RESEARCH INSTITUTE OF EYE DISEASES   (Russian Federation)

^c Innovative Vision Products Inc   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CAN C; CARNOSINE; EYE DROPS; LUBRICATING AGENT; N ACETYLCARNOSINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CAR DRIVING; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EYE TOXICITY; FEMALE; GLARE; GLARE SENSITIVITY; HALOMETER; HALOMETER GLARE TEST; HALOMETER SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REJUVENATION; SCORING SYSTEM; SHORT COURSE THERAPY; SPECTRAL SENSITIVITY; SYSTEMIC DISEASE; TRAFFIC SAFETY; VISION TEST; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AUTOMOBILE DRIVING; CARNOSINE; CATARACT; DOUBLE-BLIND METHOD; FEMALE; GLARE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; VISION DISORDERS; VISUAL ACUITY;

EID: 6344274981     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2004.7.186     Document Type: Article

References (51)

1. Babizhayev MA, Seguin MC. Process of assessment of ocular dysfunctions and implementation devices of this process. U.S. Patent No. 6,007,203. Date of patent: December 28, 1999.
2. Babizhayev MA, Deyev AI, Yermakova VN, et al. Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optom 2003;86:157-172.
3. National Highway Traffic Safety Administration. Conference on Research and Development Needed to Improve Safety and Mobility of Older Drivers. Washington, DC: U.S. Department of Transportation, 1989.
4. Transportation Research Board. Transportation in an Aging Society. Vol. 1. Washington, DC: National Research Council, 1988.
5. McCoy GF, Johnson RA, Duthie RB. Injury to the elderly in road traffic accidents. J Trauma 1989;29: 494-497.
6. Barancik JI, Chatterjee BF, Greene-Cadden YC, et al. Motor vehicle trauma in northeastern Ohio: incidence and outcome by age, sex, road-use category. Am J Epidemiol 1986;74:473-478.
7. Evans L. Risk of fatality from physical trauma versus sex and age. J Trauma 1988;28:368-378.
8. Fingerhut LA, Warner M. Injury Chartbook: United States, 1996-97. Hyattsville, MD: National Center for Health Statistics, 1997.
9. Owsley C, McGwin GJ. Vision impairment and driving. Surv Ophthalmol 1999;43:535-550.
10. Owsley C, Stalvey BT, Wells J, et al. Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol 2001;119:881-887.
11. Wolbarsht ML. Tests for glare sensitivity and peripheral vision in driver applicants. J Safety Res 1977;9: 128-139.
12. Pulling NH, Wolf E, Sturgis SP, et al. Headlight glare resistance and driver age. Hum Factors 1980;22:103-112.
13. Babizhayev MA. Glare disability and driving safety. Ophthalmic Res 2003;35:19-25.
14. Klein BEK, Klein R, Linton KLP. Prevalence of age-related lens opacities in a population: the Beaver Dam Eye Study. Ophthalmology 1992;99:546-552.
15. Rubin GS, Adamson IA, Stark WJ. Comparison of acuity, contrast sensitivity, and disability glare before and after cataract surgery. Arch Ophthalmol 1993; 111:56-61.
16. Heuer DK, Anderson DR, Knighton RW, et al. The influence of simulated light scattering on automated perimetric threshold measurements. Arch Ophthalmol 1988;106:1247-1251.
17. Adamsons I, Rubin GS, Vitale S, et al. The effect of early cataracts on glare and contrast sensitivity. A pilot study. Arch Ophthalmol 1992;110:1081-1086.
18. Elliott DB, Gilchrist J, Whitaker D. Contrast sensitivity and glare sensitivity changes with three types of cataract morphology: are these techniques necessary in a clinical evaluation of cataract? Ophthalmic Physiol Opt 1989;9:25-30.
19. Lasa MS, Datiles MB, Podgor MJ, et al. Contrast and glare sensitivity. Association with the type and severity of the cataract. Ophthalmology 1992;99:1045-1049.
20. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14: An index of functional impairment in patients with cataract. Arch Ophthalmol 1994;112:630-638.
21. Mangione CM, Phillips RS, Seddon JM, et al. Development of the activities of daily vision scale: a measure of visual functional status. Med Care 1992;30: 1111-1126.
22. Applegate WB, Miller ST, Elam JT. Impact of cataract surgery with lens implantation on vision and physical function in elderly patients. JAMA 1987;257: 1064-1066.
23. Cataract Management Guideline Panel. Cataract in Adults: Management of Functional Impairment: Clinic Practice Guideline. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, 1993.
24. Owsley, C, Stalvey B, Wells J, et al. Older drivers and cataract:driving habbits and crash risk. J Gerontol Med Sci 1999;54:M203-M211.
25. McGwin G, Chapman V, Owsley C. Visual risk factors for driving difficulty among older drivers. Accid Anal Prev 2000;32:735-744.
26. Ball K, Owsley C, Stalvey B, et al. Driving avoidance and functional impairment in older drivers. Accid Anal Prev 1998;30:313-322.
27. Babizhayev MA, Deyev AI, Yermakova VN, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R&D 2002;3:87-103.
28. Babizhayev MA, Deyev AI, Yermakova VN, et al. N-Acetylcarnosine, a natural histidine-containing di-peptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001;22:979-994.
29. Babizhayev MA, Yermakova VN, Deyev AI, et al. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med 2000;3:43-62.
30. Ferris FL, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-96.
31. Ferris FL, Sperduto RD. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol 1982;94:97-98.
32. Babizhayev MA, Bozzo Costa E. Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority Oct. 15, 1993.
33. Babizhayev MA, Bozzo Costa E. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct. 10, 1994.
34. Babizhayev MA. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication Date: 8 April 2004.
35. Colsher PL, Wallace RB. Geriatric assessment and driver functioning. Clin Geriatr Med 1993;9:365-375.
36. Wright IS. Keeping an eye on the rest of the body. Ophthalmology 1987;94:1196-1198.
37. Fishman GA, Baca W, Alexander KB, et al. Visual acuity in patients with best vitelliform macular dystrophy. Ophthalmology 1993;100:1665-1670.
38. Wu DZ, Wu L, Chang FX, et al. Visual rehabilitation in low vision patients with aging macular degeneration. J Am Optom Assoc 1995;66:39-41.
39. Carter TL. Age-related vision changes: a primary care guide. Geriatrics 1994;49:37-47.
40. Klein R. Age-related eye disease, visual impairment, and driving in the elderly. Hum Factors 1991;33:521-525.
41. Welner AH. The driving environment and visual disability. Am J Phys Med 1987;66:133-137.
42. Scharwey K, Krzizok T, Herfurth M. Night driving ability of persons with normal vision and variable age. Ophthalmologe 1998;95:555-558.
43. Rubin GS, Roche KB, Prasada-Rao P, et al. Visual impairment and disability in older adults. Optom Vis Sci 1994;71:750-760.
44. Mantyjarvi M, Tuppurainen K. Cataract in traffic. Graefes Arch Clin Exp Ophthalmol 1999;237:278-282.
45. Elliott DB, Bullimore MA, Patla AE, et al. Effect of a cataract simulation on clinical and real world vision. Br J Ophthalmol 1996;80:799-804.
46. Munton G. Cataract and driving. Br J Ophthalmol 1997;81:3-4.
47. Busse H. Visual acuity and automobile driving fitness in the elderly. Fortschr Med 1993;111:274-278.
48. Elliott DB, Bullimore MA. Assessing the reliability, discriminative ability, and validity of disability glare tests. Invest Ophthalmol Vis Sci 1993;34:108-119.
49. Van den Berg TJTP. Importance of pathological intraocular light scatter for visual disability. Doc Ophthalmol 1986;61:327-333.
50. Babizhayev MA, Yermakova VN, Sakina NL, et al. N-Acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin Chim Acta 1996;254:1-21.
51. Babizhayev MA. Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta 1996;1315:87-99.